Hill's Pet Nutrition is offering veterinary surgeons, vet students and nurses in the UK an opportunity to look round its Pet Nutrition Centre in Topeka, Kansas, via a live webcast to be delivered at 7pm on Tuesday 11th January 2011.
To join the webcast, which will last around 1.5 hours, go to http://www.fc-tv.com/webcast/keystone/hills/jan-11-11 and enter the password pnctour. This event is specifically for veterinary surgeons, veterinary students and veterinary nurses only.
Tim Dobbins, Associate Veterinary Affairs Manager said: "We look forward to our colleagues joining us for this special live webcast and hearing some of the latest thinking that explains the science behind some of our most exciting products."
Omniflora paste is designed to provide fast acting support in acute digestive upset or strategically ahead of perceived stressful events such as travel or veterinary appointments.
It contains probiotics, prebiotics, adsorbents, parabiotics, postbiotics, electrolytes and nutrients.
Omniflora tablets are available for animals who resist an oral syringe.
The tablets contain probiotics, prebiotics and adsorbent clay and fibre.
Veterinary nurse and sales manager, Tara Evans, said: “Digestive upset in cats and dogs is common.
"We wanted to provide vets and pet owners with an easy-to-use solution that can be used in practice or at home.
"One tube of paste lasts for three consecutive days to support cats and dogs as they recover from gastrointestinal upset.”
"As well as supporting the gut in acute episodes of digestive upset such as diarrhoea, Omniflora can be used ahead of time in stressful events such as travelling, visiting the groomers, or any planned veterinary procedures such as surgeries or blood tests.”
Omniflora can be ordered here https://www.vitaanimalhealth.com/product/omniflora
Cranial cruciate ligament insufficiency (CCLI) affects 3% to 5% of dogs1.
Past research has demonstrated satisfactory short (6-12 weeks)2 and medium (mean 16 months)3 term outcomes for lame dogs treated with TTA.
However, Steve says there is limited research on longer (>16 months) follow-up periods.
It has also been speculated that dogs with tibial plateau angles (TPA) of greater than 30⁰ are not well suited for a TTA4.
For the study5, the researchers reviewed patient records for a total of 149 TTA-Rapid procedures carried out in 120 dogs over an 80 month period.
They also reviewed owner questionnaires that evaluated the outcome of at least six months after surgery, using a validated clinical metrology instrument, Liverpool Osteoarthritis in Dogs (LOAD).
Follow-up questionnaires were received from owners of 64 of the 120 dogs (53.3%), with a median follow-up time of 37.5 months.
This cohort included a wide range of breeds, aged between 2&12 years and with bodyweights ranging from 6.3 to 41.8kg.
The dogs included 37 females and 27 males, and of the 79 limbs treated in these dogs, 41 were left and 38 were right.
The researchers found 26 of the dogs (40.6%) had a TTA performed with a TPA less than 30◦ and 38 (59.4%) with a TPA of 30◦ or more.
Of the 79 procedures, meniscal injury was noted in 27 (34.2%), surgery to stabilise the patella was required in 11 (13.9%), there was one surgical site infection (treated successfully with a short course of antibiotics), one dog sustained a fracture of the tibial seven days after surgery, and one sustained a late meniscal tear 12 months after initial surgery (treated successfully by partial meniscectomy).
The outcome was judged to be satisfactory, based on frequency of lameness, in 63 (98.4%), while satisfactory outcomes were achieved in 61 (95.3%) based on severity of lameness and in 50 (78.1%) based on mobility score.
Statistical analysis showed that age, bodyweight, tibial plateau angle (TPA), meniscal injury, and concurrent patellar surgery did not influence the outcome, but time to follow-up positively correlated with mobility score (suggesting mobility declined with time from surgery).
The researchers concluded that the long-term (median of 37.5 months) outcome for dogs undergoing TTA-Rapid for cranial cruciate ligament disease is satisfactory, with no risk factors associated with poorer outcomes identified.
The study also revealed no evidence to support the suggestion that dogs with TPAs of greater than 30◦ may be inappropriate candidates for TTA - after testing several parameters to judge outcome including frequency of lameness, severity of lameness, distance walked daily and mobility score.
Steve said: “This research is important in trying to ensure that decisions on whether to use this treatment modality, are based on sound clinical evidence.
"The only factor identified that influenced the outcome measure was that of time since surgery.
"All other factors, including TPA, had no effect on the outcome.”
References
VetTeamAMR includes a learning platform with information about responsible prescribing practises for the whole practice team, and an audit tool designed to support continuous improvements in national antimicrobial stewardship efforts.
The new companion animal materials complement the equine and farm animal resources which were launched earlier this month and in 2021 respectively.
RCVS Knowledge is launching VetTeamAMR for veterinary teams who treat companion animals at a free online event on Tuesday 20 June 2023 at 7:00 pm (BST).
The event is open to all to attend, and will include talks from:
Chris Gush, Executive Director at RCVS Knowledge said, “AMR is a hugely important issue for us at RCVS Knowledge and we are pleased to be able to provide veterinary teams with free tools and resources to support the responsible use of antimicrobials.
“Antibiotics remain the primary treatment for potentially fatal bacterial infections.
"Yet inappropriate use of antibiotics has led to resistance that has created a global animal and human health emergency.”.
“With busy veterinary practices in mind, we have worked alongside veterinary experts to create accessible and user-friendly VetTeamAMR tools and resources and we encourage all UK veterinary practices to get involved.”
To register for the online launch: https://knowledge.rcvs.org.uk/news-and-events/events/vetteamamr-companion-animal-launch-event/
HMRC has published advice concerning the forthcoming increase in the rate of VAT, from 17.5% to 20% on Tuesday 4th January 2011.
From 4th January, you will need to charge the new 20% VAT rate on all standard-rated sales you make and all retail takings your receive.
The new VAT fraction for the 20 per cent rate is 1/6 (used to calculate the VAT element of standard-rated gross takings).
If your business issues VAT invoices, you must use the new 20 per cent rate for all VAT invoices you issue on or after 4 January, which are issued within 14 days (or longer period that has been agreed with HMRC) of you providing the goods or services.
Supplies that span the rate changeIf you supply goods or services before 4 January 2011, but issue a VAT invoice on or after that date, you can choose to charge VAT at 17.5 per cent.
Continuous supplies of servicesFor a contract that started before 4 January you can choose to charge the old rate, 17.5 per cent, on services actually performed before 4 January, and the new rate of 20 per cent on the value of services actually performed after.
Reclaiming VATFrom 4 January 2011, you may receive VAT invoices with the new 20 per cent rate, as well as VAT invoices with the old 17.5 per cent rate for goods or services you bought before the rate changed. In such cases, you should claim back VAT at the rate shown on the invoice.
Completing a VAT returnThe deadlines for submitting VAT returns remain the same, so you should continue to submit VAT returns in the usual way - whether you send them monthly, quarterly or annually. For returns that span the change in rate, you will need to add together both the VAT on sales charged at 17.5 per cent and those charged at 20 per cent. You then put this total in box 1 of your VAT return.
Countering arrangements designed to take advantage of the VAT rate changeIn order to counter businesses taking advantage of the VAT rate change by making arrangements that aim to apply the 17.5 per cent VAT rate to goods or services to be delivered or performed on or after 4 January 2011, anti-forestalling legislation has been introduced. Further details of this can be found in the web link below.
Further informationHMRC has published detailed guidance on the rate change, which can be found at www.businesslink.gov.uk/vatratechange/.
76 vets, 34 nurses and 7 other practice staff took part in the survey, which was conducted at the VetsNow ECC Virtual Congress. Participants were asked a number of questions on antibiotic resistance and UTI management.
47% of vets said they currently feel confident prescribing antibiotics for suspected UTIs in the absence of culture and sensitivity results. However, 84% would be confident if they were able to use a rapid in-house sensitivity test.
77% of the participants said they were concerned about the increasing emergence of antimicrobial resistance.
Rachel Kirkby MRCVS, Business Development Director, said: "Antibiotic resistance is a huge threat to both human and animal healthcare across the world. We all need to work together to address it, and at Test and Treat we want to make it easier for vets in practice to do their bit by prescribing antibiotics according to best practice."
Test and Treat says the problem is that while many vets are keen to tackle resistance, it is not always easy to avoid empirical prescribing in practice. Of the vets surveyed, 65% reported that they are typically not able to obtain an accurate clinical diagnosis prior to prescribing antimicrobial therapy.
Rachel said: “It can be frustrating for vets to have to prescribe empirically when they don’t have any information on antibiotic sensitivity. But logistical constraints often mean that it’s not practical to send samples off to the lab.”
Test and Treat's U-Treat system consists of two rapid tests: a 5-minute assay that can confirm the presence of infection and a 30-minute assay that evaluates antibiotic sensitivity. With this diagnostic tool, vets can therefore select and prescribe the most appropriate antibiotic within an hour.
Rachel said: "Since you get results so quickly, you can use the test while the owner waits – or, in the current situation, more likely goes for a walk and comes back. This means that vets can get their patients started on the most appropriate treatment right away.”
U-Treat is currently validated for use in dogs and cats, but company says it is also looking to license it in rabbits and human healthcare.
To find out more about U-Treat, contact Test and Treat’s National Sales Manager Jo Nickerson on Jo.Nickerson@tandtreat.com or visit http://www.tandtreat.com.
The grants, which are for up to £3,500 per annum, are for students embarking on a gateway or main veterinary degree course, possibly as a second degree.
Amber Cordice was an early recipient of a Quadstar Foundation grant which she has had for the last four years.
She'd always wanted to be a vet, but didn't quite get the A level grades, so she took an undergraduate Zoology degree and got a first.
She was then awarded a place at Harper and Keele Veterinary School, but just didn't have the money because there is no finance for second degrees.
So the enterprising student set up a 'Go Fund Me Page' which got reported by VetSurgeon.org News, which is how Nick found out about her challenges and the rest is history.
Except not quite, because then Alicia Guarnieri (pictured) found herself in a similar position.
She'd completed a degree in Bioveterinary Science before starting a vet degree at the University of Bristol.
She said: “I’d managed to save up prior to being offered my place but when Covid hit, most of it went on rent.
"Like Amber, I decided to defer my place. I looked everywhere for grants, spending hours sifting through guides and asking all the vets I knew, but it all came to a dead end."
But then she came across Amber's story on VetSurgeon.org and, through her, found out about the Quadstar Foundation which awarded her with a grant which covers over a third of her tuition costs.
Alicia added: “Finances are a huge barrier to students taking a second degree, particularly after tuition fees increased.
"There are many of us in the same boat, and sadly many who turn down their place solely due to cost.
"Nick and the Quadstar Foundation are truly changing people’s lives by offering this support.
"Having thought I would never get to this point, I can’t wait to qualify next year and finally become a vet, and I am forever grateful for the help The Quadstar Foundation has provided me.”
Quadstar's latest grantee is Raluca Magadan, a veterinary nurse from Ireland, who is now on the accelerated graduate course at Bristol University.
She said: “Doing a second degree was never going to be easy.
"However, through help from family and locum vet nurse work, I managed to afford my first three years of vet school and made it into final year.
"This is where the difficulty came, as I had to more than forty hours per week of unpaid rotations work, plus clinical EMS during the holiday breaks, which made it very hard for me to earn the money I needed to afford my final year.
"At times it meant I had under £100 to survive an entire month on, which became a big physical and mental challenge.
“That’s when the Quadstar Foundation stepped in and took a weight off my shoulders by helping to pay off my outstanding university fees and providing some financial security in my final months.
"This has been a huge relief and allowed me to finally enjoy my last year at Bristol.
"I can’t thank everyone at the charity enough.”
In addition to funding and mentoring, The Quadstar Foundation helps its grantees with everything from job applications to revision techniques, as well as any mental health crises and helping them to find a place to live.
Nick, who also runs a property and acquisitions company and Animus Surgical, a pet and vet supplies company, said: “Having worked as a vet for many years before setting up my businesses, I have great industry connections and knowledge.
"So, I’m in the privileged position of being able to help committed students to seize the career opportunities they deserve.”
“My main commercial motivation now is to be able to maintain the funding streams required for these grants.
"It’s surprisingly hard to fundraise for individuals.
"That’s why Animus Surgical has just committed to donating 15% of its profits to the Quadstar Foundation.”
He added: “It’s an enormous privilege to support these inspiring young vets who have had such a hard slog to get past the ever-increasing barriers they face. Barriers that back in our day didn’t exist.”
What a lovely story. VetSurgeon.org is proud to have played a tiny little part in it and wishes Amber, Alicia and Raluca every success in their future careers. And hats off to Nick.
www.quadstar.org
Under the previous system, complaints made about a veterinary surgeon or veterinary nurse would, at Stage One, be considered by a Case Examiner Group (CEG) which would determine if there was an arguable case of serious professional misconduct.
If the CEG found there was an arguable case, it would then refer it to Stage Two of the process for consideration by the Preliminary Investigation Committee.
The CEG stage of the process has now been replaced by Stage One Preliminary Investigation Committees which, rather than using the ‘arguable case’ threshold, will consider from the outset whether there is a realistic prospect that the alleged conduct constitutes serious professional misconduct and that there is sufficient evidence.
The new Stage One Preliminary Investigation Committees will comprise members of the professions and lay people, and will be assisted in their investigations by an RCVS Case Manager who will also be the first point of contact for those raising concerns, witnesses and respondents in the case.
Eleanor Ferguson, RCVS Registrar and Director of Legal Services, said: “By keeping to one consistent threshold for serious professional misconduct throughout the concerns investigation process, we hope that these changes will help to simplify our investigations while still ensuring that the process remains robust and thorough.
"We also hope that, in time and when the changes are fully bedded in, we may also see a swifter resolution to some cases, as concerns that may previously been referred on to Stage Two of the process can now be closed at Stage One.”
If a Stage One Preliminary Investigation Committee cannot close a case it will refer it on to a Stage Two Preliminary Investigation Committee.
This will gather additional information and evidence and then determine if there is a realistic prospect of finding serious professional misconduct and if it is in the public interest for the case to go to Stage Three - a full, public Disciplinary Committee hearing.
Eleanor added: “The introduction of these new stages is the first step in the programme of reform of our concerns investigation and disciplinary processes.
"Next year we will be looking to introduce our Charter Case Protocol which will be a way of resolving some less serious cases of alleged misconduct where it would not necessarily be in the public interest to hold a full Disciplinary Committee hearing.”
www.rcvs.org.uk/concerns
The webinars will be presented by specialists in their respective fields; small animal oncologist Sara Verganti and clinical pathologists Francesco Cian and Roberta Rasotto.
Each 30-minute session will focus on a specific aspect of MCT diagnostics followed by a multidisciplinary Q&A. The sessions, which all start at 7:30pm, are:
Dr Neil Mottram MRCVS, Technical Product Manager at Virbac said: "Mast cell tumours are the most common form of canine cutaneous neoplasia, although relatively simple to identify, knowing what diagnostic steps to take can be challenging. We believe this truly comprehensive bite size mini-series will provide vets with the confidence to navigate the diagnostic approach for their next MCTs."
For more information, contact your Virbac Territory Manager.
Zoetis says that the problem appears not to be an endemic wellbeing issue for which the answer might be to develop greater individual resilience, but rather it is a symptom of the working environment itself, fuelled by structural, cultural and economic factors.
This, the company argues, means that concentrating on individual resilience may be misguided, and a new approach is needed, one that addresses the environmental factors at play.
The white paper identifies three areas for change:
Firstly, a complete reimagining of the veterinary workplace with more flexible and sustainable working models.
This includes considering more flexible work rotas, using technology to ease workloads, and enhancing the supporting role of veterinary nurses.
Indeed the most important factor in improving workplace wellbeing and professional satisfaction, cited by 27% of vets, was to better train veterinary nurses to take on more responsibility.
Secondly, finding ways to adapt to meet growing and varied client needs.
The white paper recommends enhancing communication training, adopting technology for better client management, and offering more support for vets when managing emotionally challenging conversations with clients.
Finally, the paper calls for a rethink over how vets are selected for in the first place.
Currently, the profession draws from a pool of 96% white, 29% fee-paying, largely female people who are not representative of the market they serve.
Greater diversity in the profession, Zoetis says, delivers social benefits, strategic advantages and workplaces with broader perspectives and greater psychological safety.
Stephanie Armstrong, Regional President at Zoetis, said: “Addressing retention in the veterinary field requires looking beyond individual well-being to systemic factors.
"By fostering better work environments and providing support, we can help ensure that veterinarians continue to provide vital services to our communities.”
Zoetis is urging stakeholders across the veterinary and animal health sector to review the white paper’s insights and join a collective effort to implement solutions.
https://www2.zoetis.co.uk/about-zoetis/news-media/knowledge-hub/transforming-veterinary-practice-for-the-21st-century
According to the charity, one in ten homeless people have a pet, which is around 32,000 people in the UK. However, the majority of hostels do not accept animals, so they are unable to access accommodation.
The new StreetVet Accredited Hostel Scheme will make sure that hostels are well-equipped to support pet-owning residents. This includes having a variety of pet-friendly health, hygiene and safety policies; access to vet care including telemedicine, free provision of pet essentials, transport to vet practices when needed, emergency kennelling should the pet owner be taken ill and trained hostel team members able to offer support.
The scheme - which will roll out nationwide – has launched today with its first accredited site, The Elms in Hemel Hempstead.
The charity was able to launch the programme after winning £41,000 in funding from Purina’s BetterwithPets Prize which rewards social entrepreneurs and innovators seeking to harness the pet-human bond to tackle societal issues.
StreetVet co-founder Jade Statt MRCVS said: “Under current regulations, if people turn down housing due to 'no pets' clauses, they are told they are making themselves 'intentionally homeless' and are refused further housing assistance. Any pet lover will understand that choosing between a roof over your head and the company of your beloved pet is no choice at all.
"Our hope is that in setting up the StreetVet Accredited Hostel Scheme, fewer people will have to make this impossible choice. Access to pet-friendly hostels is their first step towards independent housing. With homelessness on the rise due to the economic impact of COVID-19, it was important to us to launch this scheme before Christmas, as winter sets in."
Bernard Meunier, Purina EMENA chief executive said: “This great achievement demonstrates how a programme built on deep love for pets and their owners, and belief in the power of the pet-human bond, can deliver positive change for both individuals and communities. And this is what we want to achieve with ourBetterwithPets Prize.”
For more information, visit https://www.streetvet.org.uk
The VMD, which reclassified the product following a request from Zoetis, says that increasing the availability of this anthelmintic should help it to be incorporated into strategic worm control programmes on farms in line with best practice guidance on worm control. This could result in long term health benefits for sheep, for example by reducing the development and spread of anthelmintic resistance, thereby prolonging the effective use of anthelmintics.
However, both the British Veterinary Association and the Sheep Veterinary Society have expressed concerns over the move.
BVA Junior Vice President John Fishwick said: "We know that resistance to anthelmintics is increasing in grazing animals worldwide and needs to be addressed to avoid a potentially disastrous situation of being unable to tackle parasites. The reclassification of Startect Dual Active from POM-V to POM-VPS is in direct opposition to the trend in Europe, where we are seeing increased control over dispensing of anthelmintics in species where resistance is posing a serious threat to animal health, welfare and profitable production; we're extremely concerned that we might start seeing resistance develop in Group 4 as a result.
"BVA believes that the prescribing of anthelmintics requires a level of control best provided by a veterinary surgeon who has the animals under his/her care, and is based on a sound clinical diagnosis. The drugs are best used as part of a flock health plan drawn up by farmers in conjunction with their vet in order to protect animal health and welfare and safeguard the efficacy of these products for the future."
Sheep Veterinary Society President Kathryn Dun said: "Group 4 anthelmintics should be used only as part of a careful designed strategy for the individual farm and it is imperative that this strategy is worked out with a vet and is part of a flock health plan for that farm. The products need to be used, in the correct way, to help prolong the life of our other anthelmintics.
"We are unlikely to have any further new groups of anthelmintics in the foreseeable future, so education of those buying and selling these products is crucial to ensure the longevity of the effective action of them against sheep parasites."
Further information on BVA's policy on anthelmintics can be found here: www.bva.co.uk/news-campaigns-and-policy/policy/medicines/anthelmintics
New research published in the Equine Veterinary Journal (EVJ) has shown that the use of standing sedation to repair lower limb fractures in racehorses produces similar results to surgery performed under a general anaesthetic, but with the advantages of less surgical complexity, time, cost and risk.
The study Short and long term results following standing fracture repair in 34 horses was conducted by Richard Payne and Polly Compston at Rossdales Equine Hospital1.
Standing fracture repair in the horse is a relatively new surgical procedure with very little follow-up data available. Treatable fractures sustained by racehorses in the UK have traditionally been repaired under general anaesthesia but it is well known that this carries an increased risk of anaesthetic-related death compared with other elective surgical procedures. However, despite the substantial increase in the number and type of surgical procedures performed under standing sedation over the past decade there has previously been very little work undertaken on standing fracture repairs.
The study looked at the case records of 34 Thoroughbred and Arab racehorses that had a lower limb fracture surgically repaired by one surgeon at Rossdales up until June 2011. The injuries included non-displaced fractures of the proximal phalanx, the third metacarpal bone and the third metatarsal bone, all of which are relatively common fracture sites in racehorses. Hospital records, owner and trainer telephone questionnaires and website research were used to evaluate follow-up. The short and long-term results were similar to those of horses undergoing repair of comparable fracture configurations under general anaesthesia, with 20 of the horses returning to racing within an average of 226 days.
This early research indicates potential for tangible benefits, including avoidance of the inherent risks of general anaesthesia as well as a reduction in surgical complexity and associated costs, leading the way for future research into larger cohorts of horses.
EVJ's Editor Celia Marr said: "The recent fatalities at the Grand National highlight that it is critical that the equine veterinary research community strives to reduce the prevalence of fractures in our racehorses. We also need to continue to seek better ways of treating those horses that do develop fractures and, while not every fracture will be amenable to this approach, this study is an important first step towards treating some of the non-displaced fractures that occur in racehorses without the need for anaesthesia."
1Short and long term results following standing fracture repair in 34 horses Richard Payne and Polly Compston, Equine Veterinary Journal ISSN 0425-1644 DOI: 10.1111/j.2042-3306.2012.00569.x
European veterinary practitioners are to receive guidance on the appropriate use of the fluoroquinolone group of antibiotics in treating a wide range of common diseases in companion animals.
The advice has been drawn up by the REQUEST team, a multinational and multidisciplinary group of experts which met for the third time last November. Their recommendations have been designed to help ensure the continued availability of this class of antibiotics in both veterinary and human medicine.
The REQUEST initiative aims to achieve a consensus on when and how to prescribe fluoroquinolones, based on a detailed assessment of published scientific data by its panel of nine acknowledged international experts. Following earlier meetings in Lyon and Vienna they have reached a stage in this ongoing project in which they can offer specific guidance on the use of fluoroquinolones in treating three important conditions in dogs: pyoderma, bacterial diseases of the upper respiratory tract and lower urinary tract infections. They will also be offering guidance on the appropriate use of this class of antibiotics in cats to avoid the development of retinal toxicities, which may occasionally result from treatment with one particular fluoroquinolone drug, enrofloxacin.
The guidance will be presented in papers to be submitted to those scientific journals which will be easily accessible to veterinary practitioners throughout Europe. Further papers will be produced and translated into the main European languages giving guidance on fluoroquinolones use in other important bacterial conditions in dogs and cats.
In the later stages of the project, the team will be highlighting priorities for future research and will use its influence to encourage collaborative studies involving the animal health industry, practitioners, veterinary schools and other research institutions, which will validate and redefine the current recommendations. They will also advise on studies which may provide the information needed in those clinical areas where there is currently insufficient published data on which to base any practical advice, such as the use of fluoroquinolones in minor companion animal species.
The REQUEST initiative is supported by Vetoquinol, a global supplier of fluoroquinolone medicines to the veterinary community. Further support is provided by the healthcare consultancy StratAdviser Ltd, which gives assistance on methodology and other scientific matters and also guarantees the independence of the expert group.
The Royal Veterinary College has carried out the first ever open-heart surgery to treat a stenotic tricuspid valve in a dog.
The three-year-old Labrador, Mabel, suffered from congenital tricuspid dysplasia. She was referred to cardiology specialists at RVC Small Animal Referrals where her tricuspid valve was found to be completely fused in the middle, with just two very small openings for her blood to flow through.
In a procedure that took a little over an hour, the RVC team examined and worked on the valve. The College reports that Mabel’s surgery was a success and her stenosis was relieved.
Mabel was subsequently found to have a moderate amount of regurgitation into the right atrial chamber, but after a few more days of additional monitoring at the RVC she was able to return home.
The surgery was carried out by Professor of Small Animal Surgery Dan Brockman at the Queen Mother Hospital for Animals. He was assisted by a team of RVC specialists to provide pre and post-operative care, including a perfusionist, a team of three anaesthetists, two surgery nurses, three surgeons and a cardiology veterinary specialist-in-training. In addition, Professor of Veterinary Cardiology Virginia Luis Fuentes and veterinary specialist-in-training Dr Rosie Payne were members of the Cardiology Service’s investigation into Mabel’s condition.
RVC students were also involved in the Mabel’s initial examinations at the hospital, providing them with an insight into the procedure. The examinations included cardiac ultrasound using the newest generation of cardiac ultrasound equipment, which is able to capture 3D and 4D images. The new ultrasound scanner was funded in part by the RVC’s charity, the Animal Care Trust.
After the surgery, the emergency and critical care (ECC) team and the Cardiology Service took over Mabel’s care, with Professor Brockman remaining involved. This saw up to four senior ECC clinicians, a number of veterinary specialists-in-training and half a dozen highly trained ECC technicians working in shifts around the clock to care for Mabel and ensure a good recovery.
According to the RVC, there have been previous attempts by veterinary surgeons to open stenotic valves with balloon valvuloplasty. However, because it is very difficult to tear the stenotic valve, this approach has not proved very successful. There is also a high risk when putting canines onto bypass. Canines have fragile blood vessels, and cannulae need to be inserted into several of these vessels, creating a danger that a major vessel tears.
Commenting on why the RVC team decided to perform this procedure at this point, and on Mabel, Dan said: "Lots of things fed into this decision. First and foremost, we had a patient whose pathology made surgery the best solution. I explained to the owner and was very honest that this procedure would be really breaking new ground. Based on what the human paediatric cardiac surgeons will do, and our limited experience of balloon-valvuloplasty suggests this is the best approach for these dogs
"The operation itself is risky, much worse than most other operations. In our hands, for this type of disease, we have about an 80% chance of getting them through the procedure. The owner has to gamble what life the dog has left against the promise of a more normal quality of life and life-span following the operation."
In relation to Mabel’s prognosis if the surgery had not been undertaken, Professor Luis Fuentes said: "It is likely that the signs of right-sided heart failure would have been more difficult to control. Her ability to exercise would have become less and less, and she would have also been at risk of having abnormal heart rhythms associated with the enlargement of the right atrium. Generally we expect them to develop more and more signs as the disease progresses. These are difficult cases to manage on a long-term basis with drugs. Her life expectancy would have been substantially reduced.
"I thought Mabel was almost a perfect candidate to have the procedure here as Dan has a lot of experience replacing tricuspid valves in dogs with tricuspid dysplasia. In those cases there is usually leaking, but Mabel’s case was unusual in that she has minimal leaking and she was most affected by the stenosis. That means you may not have to implant any additional valve structure."
Speaking two weeks after the operation, owner Annabelle Meek, from Melton Mowbray, said: "Mabel has just come back in from wandering around the perimeter of my garden for the first time since before the operation. It’s more than half an acre and she has been ambling around happily following a scent.
"I would like to thank absolutely everybody. It’s been an enormous team effort on all sides. Every single person I met at the RVC, from the man on the gate to all the hospital staff, was so friendly. After she came home Dan Brockman phoned me every day to see how she was doing. The RVC should be very proud of what they have done for Mabel."
The first meeting takes place on Thursday 27th May from 12.30pm to 1.30pm. It will look at how veterinary practices have had to work differently and adapt to the challenges posed by the coronavirus pandemic.
Chris Tufnell, RCVS Council Member and Innovation Lead (pictured right), will be chairing the session. He said: “In the past 15 months we have been in innovation overdrive, adapting at a unprecedented pace to transform how we work, serve our clients and patients, and continue to function as veterinary businesses in less-than-ideal circumstances.
"This event is an opportunity to take a step back, look at what has happened, how we have changed and consider what aspects of these changes we might carry over when we return to near normal working conditions.
"For those who join us, we would like to know what kind of innovation solutions you and your colleagues have developed, and share your stories and ideas to help and inspire others.”
Joining Chris on the panel will be a selection of veterinary professionals who will share their own experience of how they have had to adapt the way they work during the pandemic. Participants include Anita Patel, an RCVS-recognised Specialist in Veterinary Dermatology, who runs her own dermatology referral service, and Richard Artingstall, Clinical Director of Vale Referrals in Gloucestershire.
The event, which will feature short presentations followed by a reflective discussion, is free to attend and can be signed up to via its Eventbrite page at: www.eventbrite.co.uk/e/152857028487
More meetings are planned for later in the year:
If you have any questions about the sessions or would like to take part as a speaker, email the ViVet Manager, Sophie Rogers on s.rogers@rcvs.org.uk or info@vivet.org.uk
The academy will consist of three modules which will be launched in 2021. Those who complete all three modules will receive certification from Bimeda, and some exclusive branded goodies.
The first module is titled Bimeda Trace Elements in Dairy Cow Fertility & Pregnancy and is available now on Bimeda’s e-learning portal: https://bimeda-learning.co.uk. This module also accounts for 1 hour 15 minutes of CPD and vets can download a certificate when they complete the module. The module has also been accredited with 9 AMTRA points.
In the coming months Bimeda says it'll add a second module focused on the role of trace element nutrition in lamb and calf growth, and a final module focused on the role of trace elements in sheep fertility and pregnancy.
Bimeda UK General Manager Mark Cokayne said: "Trace elements play a critical role in the health and fertility of ruminants, yet historically this area has been somewhat overlooked in formal animal health education.
"Our customers tell us that they would like a deeper understanding of areas such as trace element deficiencies, toxicities and interactions, and the impact of these on ruminant health and fertility. We are pleased to respond to this market demand with our new academy, which will provide veterinarians and SQPs with additional knowledge to help inform their conversations with farmers."
To sign up to either Bimeda’s online Nutrition Academy or the Sheep Scab Academy, visit https://bimeda-learning.co.uk
For more information, speak to your Bimeda territory manager or call Bimeda on 01248 725 400.
The webinars will provide practical information to help manage renal cases, focusing on the importance of early diagnosis.
Led by feline medicine experts, Dr Tommaso Furlanello PhD ECVCP Dip and Dr Sarah Caney BVSc PhD DSAM(Feline) MRCVS, the webinars will provide practical information to help manage renal cases.
On 7th June, Tommaso's talk will address early diagnosis of feline chronic kidney disease (CKD) and recognition and management of its complications.
On the 28th, Sarah's talk will focus on supporting and communicating with cat owners around early diagnosis and achieving optimal long-term management.
The webinars will be available to watch live or as a recording after the event.
To register for the event, visit: https://purinaproplan-webinarseries.vfairs.com/
If you attend the live event, you'll have the chance to put questions to Sarah and Tommaso, but if you can't make it on the night, there'll be a recording afterwards.
The Animal Health Trust is appealing to veterinary surgeons and nurses to encourage clients who keep their horses on premises that have been affected by Equine Grass Sickness to sign up to the second year of its nationwide EGS vaccine trial.
Equine Grass Sickness (EGS) occurs predominantly in Europe, with Britain experiencing the highest incidence worldwide. In 2014, 59 cases of EGS were reported through the EGS Surveillance Scheme, but it is likely that this represents only a fraction of cases occurring annually throughout Britain.
Almost all cases of EGS occur in horses with access to grazing. The AHT says there is growing scientific evidence to suggest that the disease may be caused by the bacterium Clostridium botulinum type C, commonly found within soil and capable of producing neurotoxins to which horses are particularly sensitive. EGS occurs when a combination of risk factors trigger the production of these toxins within the horse's intestinal tract, causing damage to the nervous system and paralysis of the gut.
As similar equine diseases such as tetanus and botulism can be prevented by vaccination, it is theoretically possible that a vaccine could prevent EGS. To this end the AHT, in collaboration with the Universities of Edinburgh, Liverpool and Surrey launched the EGS field vaccine trial in 2014 in order to establish whether a vaccine could indeed be effective in reducing the risk of the disease. The trial is funded by a number of sources including Neogen Corporation; Animal Welfare Foundation; Horserace Betting Levy Board; Racing Foundation; Moredun Foundation Equine Grass Sickness Fund; Hong Kong Jockey Club; The British Horse Society and the EB Moller Charitable Trust.
Now entering its second year, the EGS vaccine trial involves enrolled horses and ponies receiving either a course of the C. botulinum type C toxoid vaccine or an inactive placebo, as well as an annual booster. The incidence of EGS is monitored throughout the trial to determine the efficacy of the vaccine, and enrolled horses and ponies are closely monitored through regular follow-ups for the duration of the trial.
With 60% of EGS cases occurring during April - June, the highest risk season for EGS is fast approaching. The AHT is appealing to owners who keep their horses on premises that have had at least one case of EGS in the past three years to enrol their horse in the vaccine trial and provide an invaluable contribution to this pioneering research prior to these high risk months. Veterinary practices with clients who fit this description are asked to help the recruitment process by encouraging suitable cases to sign up to the trial.
Dr Jo Ireland, the AHT's Equine Grass Sickness Research Co-ordinator, said: "We have been delighted with the overwhelmingly positive response to the EGS vaccine trial and many owners have welcomed the chance to be a part of such important research. We don't want any eligible horse owners to miss out on the opportunity to contribute towards a potential breakthrough in the prevention of EGS, so we are encouraging more owners to enrol their horses on the trial this year."
To find out more about the vaccine trial or how clients can enrol horses and ponies, visit the AHT's dedicated EGS website www.equinegrasssickness.co.uk or email equinegrasssickness@aht.org.uk.
The University of Surrey has announced that it is to launch a new school of veterinary medicine in 2014.
According to the University, the new school will embrace the 'One Health - One Medicine' philosophy and will include the development of a unique research-led veterinary medicine degree programme with an emphasis on research, veterinary pathology and livestock medicine.
The new school will be based at the University of Surrey's Manor Park site in Guildford, in order to encourage collaboration of students and staff from different disciplines, with those studying towards a veterinary medicine qualification being exposed to engineering and physics as well as receiving training in core business skills.
The new School of Veterinary Medicine at Surrey will be delivered through collaborations with key partners including: the Animal Health and Veterinary Laboratories Agency (AHVLA), the BBSRC Pirbright Institute, the Veterinary Medicines Directorate (VMD), Fitzpatrick Referrals, Liphook Equine Hospital and Westpoint Farm Vets. The University says it is looking to extend its relationships with regional veterinary practices over the coming year.
Students will also be exposed to global issues concerning animal health through the University Global Partnership Network (UGPN), a trilateral agreement between Surrey, North Carolina State and São Paulo Universities through teaching collaborations, summer scholarships and research exchanges.
Professor Lisa Roberts, Dean of the Faculty of Health and Medical Sciences at the University of Surrey, said: "As a research-intensive University we have the expertise, reputation, technical and business skills which our students can benefit from, allowing us to train the veterinary leaders of the future. Combining state-of-the-art facilities, our unique partnerships and a campus location, the new School will provide a stimulating environment not only for undergraduates, but for the professional development training of qualified veterinary surgeons."
Professor John Fazakerley, Director of The Pirbright Institute, said: "This is good news for the UK veterinary research community. The Pirbright Institute currently works in close collaboration with the University of Surrey on research that benefits animal health and welfare; we very much look forward to building on this established and growing association as the new school of veterinary medicine is launched. There is an important place for trained veterinarians in scientific research and we are delighted that the University has decided to emphasise these areas in particular."
Professor Andy Durham of the Liphook Equine Hospital said: "The new School of Veterinary Medicine development programme at the University of Surrey is ideally timed to provide an alternative to the traditional veterinary education and to respond to the demands of a changing profession with fresh plans, ideas and enthusiasm. Enticing newly developed facilities make Guildford an excellent student town and with several collaborative specialist partners within the locality the new School of Veterinary Medicine is perfectly placed geographically to provide a veterinary education fitting for the 21st century."
The University is also in consultation with the Royal College of Veterinary Surgeons. Freda Andrews, Head of Education at the RCVS, said: "We were pleased to meet Professor Sir Christopher Snowden, President and Vice-Chancellor and his colleagues from the University of Surrey recently, and interested to hear their proposals to develop a new School of Veterinary Medicine. We will be working with them over the coming months to develop a timetable for considering the new programme against our accreditation standards. The monitoring process will take a number of years."
The University says it has already laid the foundations for the new School through its expansion of teaching and research activities in its Faculty of Health and Medical Sciences, including the launch of the BSc programme in Veterinary Biosciences in 2009 and in October of this year a new MSc in Veterinary Microbiology. A new MSc in Veterinary Pathology is also currently under development.
The University says that over the next 12 months it will be recruiting new academic staff, attracting the first cohort of students and beginning building works in preparation for the first cohort of students in 2014.
The British Equine Veterinary Association (BEVA) has announced that it is reducing the cost of its CPD by 50% this year and making its webinars free to members.
David Mountford, Chief Executive of BEVA said: "Last year we were able to capitalise on some efficiencies in other areas of BEVA operations. We are delighted to be able to hand the resulting benefits directly back to our members across all our CPD programme during 2013."
The Association says its CPD covers a broad range of topics is aimed at busy vets who need to build CPD points, whether new graduates, equine or mixed practitioners. It takes the form of clinical workshops, regional meetings, nursing meetings, webinars and one, two and three day practical courses, held in the UK.
This year's courses include:
For more information, visit http://www.beva.org.uk/news-and-events/beva-courses or ring +44(0)1638 723555 or email info@beva.org.uk.
BVA President Gudrun Ravetz said: "Veterinary View not only highlights some of the veterinary profession's fantastic work, but complements our joint project with RCVS, Vet Futures, in exploring how the profession can best shape its own future. We hope it will stimulate debate among vets, and the wider community in which we work, about both the big challenges and opportunities that the veterinary profession is facing."
The series includes a number of videos which showcase more recent industry developments:
Stem Cell therapy for the treatment of canine osteoarthritis (VetCell Therapeutics)
Pharmtrax, a mobile device for vets to record work and dispensing on the farm (Henry Schein Animal Health)
Hormone implants as an alternative to castration (Virbac Animal Health)
Practice management support from Zoetis
Preventing an epidemic of equine flu (Merial Animal Health)
The session will be conducted in the style of the BBC Radio 4 Moral Maze discussion programme, with panelists and witnesses arguing for and against the viewpoint corporatisation is inevitable and will benefit vets and their clients.
Moderated by Madeleine Campbell, Keith Chandler and Karl Holliman will argue for corporatisation and Andrew Harrison and Tim Greet will be against. They will call upon a series of 'witnesses' for detailed questioning before the topic is more broadly debated.
CVS, the UK’s biggest veterinary group now owns more than 410 veterinary practices, of which over 30 are specifically equine or mixed practices.
The latest equine acquisitions include Bell Equine, a one-site Equine Referral Hospital in Kent, in January 2017 and Severn Edge Veterinary Group, a mixed practice with 12 sites in Shropshire, including a six-vet dedicated equine practice, in April 2017.
One line of argument says that the commercial and business advantages of a corporate, together with their scale and diversity, can give veterinary surgeons greater potential for a more flexible career path and advancement within the industry, and a more sustainable working career in equine practice.
On the flip side, there's the removal of any opportunity to buy into ownership, reduced decision-making ability because of adherence to corporate procedures, extra paperwork, longer approval processes and an increased emphasis on the bottom line.
David Mountford, Chief Executive of BEVA said: "The auditorium is usually full to bursting for our Moral Maze sessions because they bring a broader and more engaging dimension to important topics. The statement Corporatisation of equine practices is inevitable and will benefit vets and their clients is bound to generate some stimulating and possibly heated debate."
This year's BEVA Congress will be held at Liverpool Arena Convention Centre, and anyone who registers before 3rd August will receive significantly reduced booking fees.
For more information, visit: www.beva.org.uk.
The research, led by the Royal Veterinary College in collaboration with the University of Edinburgh and Nottingham Trent University, also revealed that 66% of owners would recommend their flat-faced breed to others.
Although previous RVC studies found that owners are initially attracted to brachycephalic breeds due to their distinctive appearance, this latest study has revealed that behaviour traits are a core component of why owners ‘love’ their breed and would recommend them to others; essentially, owners come for the looks, but stay for the personality.
In order to gain a deeper understanding of these views, the study, which included over 2,000 owners of Pugs, French Bulldogs and English Bulldogs, asked owners to describe which aspects of their current breed they would or would not recommend in their own words.
The main reasons for owners recommending their breed included:
Conversely, aspects of their breed that owners would not recommend included:
Dr Rowena Packer, Lecturer in Companion Animal Behaviour and Welfare Science at the Royal Veterinary College and leader of the study, said: "With a multitude of stakeholders trying to tackle the current brachycephalic boom in the UK, our results are of real concern to these efforts. Understanding how breed loyalty develops towards brachycephalic breeds, and whether it can be changed once established, is key to reducing the popularity of short-muzzled breeds. If first time owners of flat-faced dogs choose these breeds for the rest of their lives, then the current crisis could continue for decades.
"Although strong focus has been placed upon dissuading new puppy buyers from purchasing brachycephalic breeds, as they are now some of the most popular breeds in the UK, attention should also be turned to current owners. Priority should be given to developing evidence-based strategies to help these owners consider lower risk, healthier breeds when acquiring future dogs. Our novel findings start this process by highlighting the key behavioural characteristics that this owner group value."
Formerly known as BSAVA’s Scottish Congress, Alba delegates will be treated to 28 lectures, four practicals, ten hours of CPD and a commercial exhibition.
There are three lecture streams: one for vets, another for vet nurses and another open to all.
Highlights include ‘Echocardiology’ with Kieran Borgeat, ‘Dermatology: What can nurses do?’ with Sue Paterson, and ‘Wildlife Triage’ with Jenna Richardson.
The practical sessions are open to all and include sampling techniques, suturing and a ferret clinical exam.
There's a gala dinner on Friday 16th from 7:30pm, starting with a drinks reception, followed by dinner and entertainment in the evening, with a live band and ceilidh dancing.
Angela McLaughlin, Scottish Regional Chair at the BSAVA said: “We are delighted that we are returning to Scotland after three years away as this is a great event that allows vets and nurses the opportunity to improve their skills and knowledge, while visiting an idyllic part of the country!”
For BSAVA members, tickets cost £240 +VAT for vets, £165 +VAT for veterinary nurses, and £65 +VAT for students.
Day tickets and non-member tickets are also available.
There's an additional fee of £10 +VAT for all practical sessions.
Tickets for the gala dinner are £35 for delegates and £55 for guests.
If you are looking for somewhere to stay, BSAVA’s hotel booking partner, BCD Meetings & Events, can help.
www.bsavaevents.com/bsavaalba2022